logo
6 things you need to know about Alzheimer's – as drug trials bring new hope

6 things you need to know about Alzheimer's – as drug trials bring new hope

Led by an expert from the University of Nevada in the US and published in the journal Alzheimer's & Dementia: Translational Research and Clinical Interventions, the review reveals that 182 clinical trials are underway in 2025, a rise of 11% from the previous year, assessing the impact 138 potential drugs.
Notably, one-third of these drugs are repurposed medications originally developed for other conditions like diabetes, multiple sclerosis, and high cholesterol.
In response to this encouraging development, Emma Taylor, information services manager at Alzheimer's Research UK, has addressed some common misconceptions about the disease, highlighting six key facts everyone should know about Alzheimer's…
1. Alzheimer's and dementia are not the same thing
Learn the distinct difference between Alzheimer's and dementia (Alamy/PA)
'A lot of people get confused between Alzheimer's and dementia and aren't really sure what the difference is,' recognises Taylor. 'The way I describe it is that dementia is the group of symptoms – so things like memory loss, confusion, personality and behavioural changes – and Alzheimer's is one of the causes of those symptoms.'
Research generally associates Alzheimer's disease with the accumulation of two proteins, amyloid and tau, says Taylor.
'These toxic proteins damage our brain cells, which are what is used to communicate messages throughout our body,' she explains. 'Overtime, as more brain cells die, it becomes harder for our brain overall to carry out its normal functions. So, depending on where in the brain the damage starts, that indicates what kind of symptoms someone will experience.
'That's why in Alzheimer's early symptoms are often memory loss and confusion because Alzheimer's tends to, but doesn't always, start in the memory centres of the brain.'
2. There are 14 potential risk factors
'A lot of the risk factors for dementia are linked to our heart health,' says Taylor. 'So, we know that what's good for your heart is good for your brain as well.
'Things like having a healthy diet, exercising regularly, limiting the amount of alcohol you drink, not smoking, keeping your blood pressure and cholesterol under control etc is really important to improve or maintain our brain health and reduce our risk of dementia.
'These risk factors, there are 14 in total, have been linked to 45% of dementia cases worldwide. So, if those risk factors were completely eliminated, then up to 45% would be prevented or delayed.'
3. It isn't an inevitable part of ageing
'A lot of people think it's an inevitable part of ageing, but it's definitely not – we can do things to reduce our risk of dementia,' says Taylor.
While Alzheimer's disease is more common in older adults, it can also affect younger people.
'People as young as 30 have developed Alzheimer's and obviously that is quite rare, but it really does show that it's not just a part of ageing,' says Taylor. 'It's a biological disease and if something goes wrong, then we can try and find a way to make it right – that's where research comes in.'
4. It isn't just about memory loss
Memory loss is just one possible symptom of Alzheimer's (Alamy/PA)
'I think a lot of people just think of Alzheimer's as memory loss, but it can affect a lot of different aspects of someone's memory and thinking,' highlights Taylor. 'Someone might become very confused and might not be sure of the time or the date, they might misplace things a lot or put them in odd places, like putting a TV remote in the fridge.'
Alzheimer's can also really affect language skills.
'People might have problems finding the right words or understanding the meaning of words or might struggle to follow conversations, and that might mean that they become quite withdrawn,' says Taylor.
In addition, there's a lot of links between Alzheimer's and mood and behaviour changes.
'People can become low in mood. other people may become more agitated or aggressive, and that's a really heartbreaking thing for someone to go through,' says Taylor.
'People often ring us and say why would I bother going to the doctor if there's no cure yet – but I think the benefits of getting a diagnosis is that support and understanding that you get from knowing what's going on, and the ability to plan ahead,' says Taylor. 'Getting a diagnosis means you can put things in place like the lasting power of attorney and sort out your will and finances while you have time.
'Getting an early diagnosis also means getting those treatments while they're likely to work best, and a diagnosis also provides more opportunities to take part in research, so the future generations don't have to go through the same thing.'
6. Remember to be patient with loved ones who have Alzheimer's
Patience and understanding are key (Alamy/PA)
'Someone might change quite a lot when they have Alzheimer's, but it doesn't mean that they deep down aren't the same person,' emphasises Taylor. 'Someone's behaviour might change quite drastically throughout the course of the disease but it's not coming from a bad place.
'So, patience and understanding is really key when dealing with anyone with any form of dementia. Treasure the time that you have with them.'
For more information about dementia, dementia research or taking part in research, visit Alzheimer's Research UK's website or contact its Dementia Research Infoline on 0300 111 5111 or email infoline@alzheimersresearchuk.org

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alzheimer's blood test ‘can accurately pick up early symptoms'
Alzheimer's blood test ‘can accurately pick up early symptoms'

North Wales Chronicle

time15 hours ago

  • North Wales Chronicle

Alzheimer's blood test ‘can accurately pick up early symptoms'

Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'

Alzheimer's blood test ‘can accurately pick up early symptoms'
Alzheimer's blood test ‘can accurately pick up early symptoms'

South Wales Guardian

time15 hours ago

  • South Wales Guardian

Alzheimer's blood test ‘can accurately pick up early symptoms'

Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'

Alzheimer's blood test ‘can accurately pick up early symptoms'
Alzheimer's blood test ‘can accurately pick up early symptoms'

Leader Live

time15 hours ago

  • Leader Live

Alzheimer's blood test ‘can accurately pick up early symptoms'

Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store